Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology

T.H. Oude Munnink; M.J. Henstra; L.I. Segerink; K.L.L. Movig; P. Brummelhuis-Visser

doi:10.1002/cpt.211

Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology

T.H. Oude Munnink, M.J. Henstra, L.I. Segerink, K.L.L. Movig, P. Brummelhuis-Visser

Research output: Contribution to journal › Article › Academic › peer-review

74 Citations (Scopus)

55 Downloads (Pure)

Abstract

Lack of response to monoclonal antibodies (mAbs) has been associated with inadequatemAb serumconcentrations. Therapeutic drugmonitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability ofmAb pharmacokinetics, summarizes exposureresponse data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementingmAb-TDM.

Original language	English
Pages (from-to)	419-431
Number of pages	13
Journal	Clinical pharmacology & therapeutics
Volume	99
Issue number	4
DOIs	https://doi.org/10.1002/cpt.211
Publication status	Published - Apr 2016

Keywords

2023 OA procedure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cpt.211

ArticleFinal published version, 469 KBLicence: Taverne

Cite this

@article{ac154bb6b5e142eab5136711bd59d02b,

title = "Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology",

abstract = "Lack of response to monoclonal antibodies (mAbs) has been associated with inadequatemAb serumconcentrations. Therapeutic drugmonitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability ofmAb pharmacokinetics, summarizes exposureresponse data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementingmAb-TDM.",

keywords = "2023 OA procedure",

author = "{Oude Munnink}, T.H. and M.J. Henstra and L.I. Segerink and K.L.L. Movig and P. Brummelhuis-Visser",

year = "2016",

month = apr,

doi = "10.1002/cpt.211",

language = "English",

volume = "99",

pages = "419--431",

journal = "Clinical pharmacology & therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology

AU - Oude Munnink, T.H.

AU - Henstra, M.J.

AU - Segerink, L.I.

AU - Movig, K.L.L.

AU - Brummelhuis-Visser, P.

PY - 2016/4

Y1 - 2016/4

N2 - Lack of response to monoclonal antibodies (mAbs) has been associated with inadequatemAb serumconcentrations. Therapeutic drugmonitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability ofmAb pharmacokinetics, summarizes exposureresponse data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementingmAb-TDM.

AB - Lack of response to monoclonal antibodies (mAbs) has been associated with inadequatemAb serumconcentrations. Therapeutic drugmonitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability ofmAb pharmacokinetics, summarizes exposureresponse data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementingmAb-TDM.

KW - 2023 OA procedure

U2 - 10.1002/cpt.211

DO - 10.1002/cpt.211

M3 - Article

SN - 0009-9236

VL - 99

SP - 419

EP - 431

JO - Clinical pharmacology & therapeutics

JF - Clinical pharmacology & therapeutics

IS - 4

ER -

Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this